Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Biomarkers for Prostate and Bladder Cancer

Biomarkers for Prostate and Bladder Cancer

114
Liu, Alvin Y.University of Washington
CD90, AGR2, CEACAM5
Case/control
Proteomics
Genomics
Prostate and Urologic Cancers Research Group

CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, CD49a+ stromal and CD31+ endothelial was carried out to identify candidates: CD90, AGR2, BCMP11, CEACAM5, CRISP3. Quantitative protomics was applied to measure these proteins in urine samples.

Sort cancer cells from tumor specimens Determine gene expression (transcriptome) by Affymetrix DNA arrays Dataset analysis to identify cancer up-regulated genes encoding secreted or extracellular proteins Proteomic analysis (mass spectrometry, Western blotting) to validate increased cancer expression
Genomics and proteomics. DNA microarray analysis of sorted cell types to identify cancer-specific genes encoding secreted/extracellular proteins. Mass spectrometry-based proteomics to measure protin levels in case vs. control urine samples.
Data analysis was done to evaluate data quality of Affymetrix arrays (mRNA expression correlation to protein expression by immunohistochemistry), to compare other publicly available prostate cancer datasets.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html